The Claim
International evidence-based guidelines from 2023 recommend classifying individuals with polyendocrine metabolic ovarian syndrome during pregnancy as higher-risk to improve screening, prevention, and management of associated complications.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Guidelines from 2023 state that pregnant individuals with polyendocrine metabolic ovarian syndrome should be identified as higher-risk to enhance detection, prevention, and treatment of related health issues.
See the scientific wording
The 2023 international evidence-based guidelines recommend classifying individuals with polyendocrine metabolic ovarian syndrome (PMOS) as 'higher-risk' during pregnancy to improve screening, prevention, and management of associated complications.
Women with this condition have high insulin and testosterone levels before pregnancy. During pregnancy, the body naturally becomes more resistant to insulin, but their bodies cannot adjust, so blood sugar rises. At the same time, fat tissue and the placenta release more inflammatory signals, damaging blood vessels and reducing nutrient flow to the baby. This causes high blood pressure, diabetes, early birth, and low birth weight.
What the research says
1 studyStudy: Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes.
The study says that women with PMOS are more likely to have problems during pregnancy, like diabetes or high blood pressure, so new guidelines now say they should get extra care — and that’s exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.